CTLA4 and neoplasm: Tumor heterogeneity has been described for key modulators of the ICB response such as PD-L1 [67], and the neoantigens and tumor clonality has already been reported as a predictor of enhanced response to anti-CTLA4 and anti-PD-1 treatment in NSCLC [68].